Pharmidex's 2024 wrapped
January 10, 2025

We are pleased to share that Janette Dalay Robertson will be attending Cell & Gene Therapy 2026 taking place 9–10 March 2026 at Hinxton Hall Conference Centre, Cambridge. This event is a fantastic opportunity to connect with leaders across the cell and gene therapy ecosystem and Janette will be there representing Pharmidex and discussing how our scientific services support drug discovery and development. 🤝 Janette would be delighted to meet with fellow attendees to: • Explore new collaborations • Discuss upcoming research programs • Share how Pharmidex can support innovative therapeutic development If you are attending, feel free to reach out and arrange a meeting during the event. We look forward to engaging conversations and building new partnerships within the cell and gene therapy community!

🔬 Unlock deeper insights into how your compound is processed in the body with Pharmidex ’s Drug Metabolism Services. At Pharmidex , we provide specialist drug metabolism studies using advanced UHPLC-high resolution/accurate mass spectrometry to support biotransformation understanding, cross-species metabolite profiling and structural characterisation of metabolites. Our expert team can help you address challenges such as high clearance, identification of metabolically labile sites and potential reactive metabolism liabilities, helping you make data-driven decisions early in the discovery and development process. Learn how our tailored approach can strengthen your metabolic profiling and accelerate your drug development programmes: 🔗 https://www.pharmidex.com/Drug-Metabolism-Service

At Pharmidex , we deliver industry-leading Discovery Bioanalysis services grounded in advanced LC-MS technologies to enhance drug discovery and preclinical research, supporting internal studies but also analyzing external samples also Our experienced bioanalytical team works across a wide range of therapeutic modalities, from small molecules and peptides, to oligonucleotides and complex biologics, providing robust, reliable and fit-for-purpose data to accelerate your program and strengthen decision-making during early development. We support both non-GLP and GLP/GCP workflows, method development, validation, and quantitative analysis that align with regulatory needs and industry expectations. Learn more about how our LC-MS capabilities can help you confidently advance your projects: 🔗 https://www.pharmidex.com/Discovery-Bioanalysis





